1. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation 
Aline Clavert, Zinaida Peric, Eolia Brissot, Florent Malard, Thierry Guillaume, Jacques Delaunay, Viviane Dubruille, Steven Le Gouill, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Jean-Luc Harousseau, Philippe Moreau, Noel Milpied, Mohamad Mohty, Patrice Chevallier 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 1, Pages (January 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Overall survival of patients who survived at least 2 years after allo-SCT (81%; 95% CI, 71% to 94%) at 10 years after allo-SCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidence of secondary malignancies (11%; 95% CI, 5% to 20%) at 10 years after allo-SCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Cumulative incidence of limited cGVHD (48%; 95% CI, 39% to 57%) and extensive cGVHD (18%; 95% CI, 12% to 26%) at 10 years after allo-SCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Cumulative incidence of cardiovascular complications (47%; 95% CI, 35% to 59%), pulmonary complications (33%; 95% CI, 21% to 46%), renal impairment (34%; 95% CI, 25% to 43%), and endocrine disorders (13%; 95% CI, 7% to 21%) at 10 years after allo-SCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions